- Home
- ADXN vs CLGN Comparison
ADXN vs CLGN Comparison
Compare ADXN & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | CLGN |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | Switzerland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.2M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADXN | CLGN |
|---|---|---|
| Price | $2.93 | $4.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 39.5K |
| Earning Date | 11-09-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $767.75 | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $0.26 |
| 52 Week High | $10.43 | $4.78 |
Technical Indicators
Market Signals| Indicator | ADXN | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 65.42 |
| Support Level | $2.60 | $0.34 |
| Resistance Level | $3.25 | $4.62 |
| Average True Range (ATR) | 0.19 | 0.37 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 47.48 | 78.68 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.